

OIR
APR 20 2003
U.S. PATENT & TRADEMARK OFFICE

Sheet 1(A) of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431
								APPLICANT Moore et al.	
								FILING DATE October 8, 2003	GROUP 1714
		(Use several sheets if necessary) (37 CFR 1.98(b))							

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
VR	A.A	2	5	1	9	8	8	6	08/22/1950	Charpentier et al.		
VR	A.B	2	8	3	7	5	1	8	06/03/1958	Jacob et al.		
VR	A.C	8	5	1	9	5	1		10/19/1960	Smith Kline & French Labs.		
	A.D											
	A.E											
	A.F											
	A.G											
	A.H											
	A.I											
	A.J											
	A.K											

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

VR	A.R	Dahl et al., <u>Binding Affinity of Levomepromazine and Two of its Major Metabolites to Central Dopamine and alpha-Adrenergic Receptors in the Rat</u> , PHARMACOLOGY, Vol. 74, 1981, pp. 101-104, XP009044395
VR	A.S	Hals et al., <u>Muscarinic Cholinergic and Histamine H1 Receptor Binding of Phenothiazine Drug Metabolites</u> , LIFE SCIENCES Vol. 43, No. 5, 1988, pp. 405-412, XP002318791
VR	A.T	Hals et al., <u>Phenothiazine Drug Metabolites: Dopamine D2 Receptor, Alpha-1 and Alpha-2 Adrenoreceptor Binding</u> , EUROPEAN JOURNAL OF PHARMACOLOGY, Vol. 125, 1986 pp. 373-381, XP009044426

EXAMINER <i>Chait Chawla</i>	DATE CONSIDERED <i>8/24/2006</i>
---------------------------------	-------------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Keith Moore			
		FILING DATE October 8, 2003		GROUP 1714	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A								
	B.B								
	B.C								
	B.D								
	B.E								
	B.F								
	B.G								
	B.H								
	B.I								
	B.J								
	B.K								

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

UR	B.R	International Search Report for PCT/US2004/032956, <u>mailed March 10, 2005</u>
	B.S	
	B.T	

EXAMINER <i>Chet Gherardi</i>	DATE CONSIDERED <i>8/24/2006</i>
----------------------------------	-------------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Keith Moore	
(Use several sheets if necessary) (37 CFR 1.98(b))				FILING DATE October 8, 2003	GROUP 1714

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>Ch</i>	A.L	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	A.R	Dahl, Svein G., <u>Pharmacokinetics of methotriptazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442
	A.S	Dahl, Svein G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40
	A.T	Dahl, Svein G. et al., <u>Plasma and Erythrocyte Levels of Methotriptazine and Two of Its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87

EXAMINER	DATE CONSIDERED
<i>Chad Chabal</i>	8/24/2004

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Keith Moore	
				FILING DATE October 8, 2003	GROUP 1714

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>UR</i>	B.R	Gennaro, Alfonso R, Ed., <u>Chapter 45 Oral Solid Dosage Forms</u> , Remington: The Science and Practice of Pharmacy, 20th Edition, 2000, Mack Publishing Co., PA, pp.878-893
<i>CR</i>	B.S	Gibson, Ed., <u>Pharmaceutical Preformulation and Formulation</u> , IHS Health Group, Englewood CO, 2001 pp. 331-354, 379-458
<i>UR</i>	B.T	Hals, PA et al., <u>Metabolism of levomepromazine in man</u> , European Journal of Drug Metabolism and Pharmacokinetics, 1995; 20:61-71

EXAMINER	DATE CONSIDERED	
<i>Chet Steward</i>	<i>8/24/2006</i>	

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Keith Moore	
				FILING DATE October 8, 2003	GROUP 1714

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>UR</i>	C.R	Sztruhar, I et al., <u>Liquid chromatographic resolution of the enantiomers of psychotropic drug levomepromazine (methotriptazine) with beta-cyclodextrin-bonded chiral stationary phase</u> , Journal of Pharmaceutical & Biomedical Analyses, 1993; 3:263-266
	C.S	
	C.T	

EXAMINER	DATE CONSIDERED
<i>Chay Stensel</i>	<i>8/24/2003</i>

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.